Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Apr 30;63(2):65-67.
doi: 10.5114/reum/204012. eCollection 2025.

Interleukin-6 signalling: what rheumatologists should know and expect

Stefano Rodolfi  1   2 , Maria Maślińska  3 , Carlo Selmi  1   2
Affiliations
Editorial

Interleukin-6 signalling: what rheumatologists should know and expect

Stefano Rodolfi et al. Reumatologia. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Interleukin-6 receptor family. CNTF – ciliary neurotrophic factor, gp130 – glycoprotein 130, IL – interleukin, LIF – leukaemia inhibitory factor Source: Created in BioRender. https://BioRender.com/5bolsth
Fig. 2
Fig. 2
Basic principles of IL-6 signalling and inhibition. Antibodies targeting IL-6 or IL-6 receptor block indistinctively classical and trans-signalling, while inhibitors of glycoprotein 130 (gp130), here represented by the pioneer sgp130Fc (i.e. olamkicept), selectively inhibit trans-signalling. JAKi – Janus kinase inhibitor, mAb – monoclonal antibody.
See this image and copyright information in PMC

References

    1. Kang S, Narazaki M, Metwally H, Kishimoto T. Historical overview of the interleukin-6 family cytokine. J Exp Med 2020; 217: e20190347, DOI: 10.1084/jem.20190347. - DOI - PMC - PubMed
    1. Aletaha D, Kerschbaumer A, Kastrati K, et al. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Ann Rheum Dis 2023; 82: 773–787, DOI: 10.1136/ard-2022-222784. - DOI - PubMed
    1. Rose-John S. Local and systemic effects of interleukin-6 (IL-6) in inflammation and cancer. FEBS Lett 2022; 596: 557–566, DOI: 10.1002/1873-3468.14220. - DOI - PubMed
    1. McElvaney OJ, Curley GF, Rose-John S, McElvaney NG. Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respir Med 2021; 9: 643–654, DOI: 10.1016/S2213-2600(21)00103-X. - DOI - PMC - PubMed
    1. Rose-John S. Interleukin-6 signalling in health and disease. F1000Res 2020; 9: F1000 Faculty Rev-1013, DOI: 10.12688/f1000research.26058.1. - DOI - PMC - PubMed

Publication types

LinkOut - more resources